How it all started
Osstell is the global leader in implant stability measurement and osseointegration progress monitoring. Osstell was formed in 1999 to commercialize an invention using Resonance Frequency Analysis (RFA) to determine the clinical status of a dental implant. More than 1 300 scientific publications confirm the benefits of the technology, its clinical value, and the use of the ISQ scale for dentists in their daily practices. Osstell is headquartered in Gothenburg, Sweden – the birthplace of dental implants. Since 2018, Osstell is part of the W&H group, one of the world’s leading manufacturers of dental precision instruments and devices.
OVER 20 YEARS EXPERIENCE
MORE THAN 1300 SCIENTIFIC PUBLICATIONS
Our method eliminates chance. When measuring the implant stability, you will get an objective value, making the implant treatment more predictable – even for patients with risk factors.
Reduced treatment time
Immediate loading is becoming more and more common. Patients want results fast. With Osstell®, you only wait as long as needed.
Backed by more than 1300 scientific studies, our method is based on RFA to determine whether or not an implant is stable enough. The result is presented as an ISQ value of 1-100. The higher the ISQ, the more stable the implant.
As a surgical specialist, I work closely with my restorative colleagues. When immediate and early loading treatment is selected, I need certainty in communicating implant stability. Osstell ISQ gives me a “number” I can provide as a tangible measurement of stability. If changes in loading protocols are appropriate, I can provide a numerical value that makes sense and keeps all members of the team on the same page. I value this technology and feel it has only just begun to demonstrate all of its applications in clinical practice.
Barry P. Levin, D.M.D
The ability to better diagnose implant stability and integration by resonance frequency analysis has provided improved confidence of the treating team as well as better patient management. It has also distinguished Misch Implant Dentistry as a practice that utilizes the latest technology available to provide superior care
Dr Craig Misch and Dr Katherine Misch
OUR SCIENTIFIC ADVISORS
Prof. Daniel Buser
Professor and Chairman, Dept. of Oral Surgery and Stomatology, School of Dental Medicine, University of Bern, Switzerland
Prof. Peter K. Moy
Oral & Maxillofacial Surgeon, Professor, Oral & Maxillofacial Surgery, UCLA, Los Angeles, USA, Director, Implant Dentistry
Dr. Marcus Dagnelid
DDS, Board Certified Prosthodontist
CEO, Chief of Staff, Dagnelid Clinic & Falkenberg Clinic, SAACD AB
CEO, European Dental Academy
Prof. Neil Meredith
Professor in Prosthodontics, University of Queensland, Brisbane, Australia
our board of directors
Chairman of the Board
Background: International experiences in leading positions in aeronautic and health care industries. Vice President Finance and Distribution for the W&H Group since 2009.
Other assignments: CEO of W&H Sterilization S.r.l., major roles and assignments in several other W&H companies
Background: More than 30 years experience in the W&H Group in different leading positions.
Vice President Group Operations for the W&H Group since 2020.
Background: More than 25 years of experience in the life science and MedTech industry with leading and CEO positions in growth companies such as Applied Biosystems, Kovalent, Cellectricon and Mentice.
Board member, Leading Light AB
Chairman of the Board, Gapwaves AB
Board Member, Doxa AB
Our Management Team